Overview
Compare with Amphastar Pharmaceuticals, Inc., Pacira BioSciences, Inc. or Emergent BioSolutions, or pick any stock.
- TickerSUPN on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersRockville, United States2
- Incorporated inDE3
- Business address9715 Key West Avenue, Rockville, Md 208503
- Filer categoryLarge accelerated filer3
- Legal formCorporation2
- LEI549300GRM36VBKISYJ582
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 39475842
See how the biggest companies compare on our leaderboards
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-8.7%Operating margin6
-5.4%Net margin6
8.6%Revenue growth, 20256
-3.6%Return on equity6
$46.0MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Qelbree brought in 42% of the revenue SUPERNUS PHARMACEUTICALS, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Qelbree | $140.2M | $241.3M | $304.7M |
| Gocovri | $119.6M | $130.8M | $146.8M |
| Collaboration Revenue | $0 | $0 | $53.0M |
| Apokyn | $75.1M | $73.9M | $47.8M |
| Trokendi Xr | $94.3M | $63.2M | $42.4M |
| Oxtellar X R | $113.4M | $99.5M | $40.7M |
| Royalty, License And Other Revenue | $33.6M | $24.1M | $39.4M |
| Manufactured Product, Other | $31.3M | $29.0M | $26.9M |
| Onapgo | $0 | $0 | $17.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue10¢$74.6M
- Research and development15¢$106.2M
- Selling, general and admin68¢$485.6M
- Other costs6¢$42.1M
- Income tax1¢$10.5M
Out of $719.0M in revenue.6 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending3¢$1.3M
- Kept or used elsewhere97¢$46.0M
Out of $47.3M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $719.0M | $661.8M | $607.5M |
| Cost of revenues | $74.6M | $77.9M | $83.8M |
| Research and development | $106.2M | $108.8M | $91.6M |
| Selling, general and administrative | $485.6M | $321.6M | $336.4M |
| Amortization of intangible assets | $89.5M | $78.0M | $82.4M |
| Intangible asset impairment charges | $0 | $0 | $20.2M |
| Contingent consideration loss (gain) | $25.4M | -$6.1M | -$1.5M |
| Total costs and expenses | $781.2M | $580.2M | $612.8M |
| Operating earnings (loss) | -$62.3M | $81.7M | -$5.3M |
| Interest and other income, net | $13.3M | $16.2M | $10.5M |
| Interest expense | $0 | $0 | -$2.4M |
| Total other income (expense), net | $13.3M | $16.2M | $8.0M |
| Earnings (loss) before income taxes | -$49.0M | $97.9M | $2.8M |
| Income tax expense (benefit) | -$10.5M | $24.0M | $1.5M |
| Net earnings (loss) | -$38.5M | $73.9M | $1.3M |
| Basic (in dollars per share) | -$0.68 | $1.34 | $0.02 |
| Diluted (in dollars per share) | -$0.68 | $1.32 | $0.02 |
| Basic (in shares) | 56.5M shares | 55.1M shares | 54.5M shares |
| Diluted (in shares) | 56.5M shares | 56.0M shares | 55.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $128.4M | $69.3M | $75.1M | |
| Marketable securities | $180.2M | $384.3M | ||
| Accounts receivable, net | $187.8M | $142.1M | ||
| Inventories, net | $82.4M | $54.3M | ||
| Prepaid expenses and other current assets | $65.3M | $36.1M | ||
| Total current assets | $644.2M | $686.1M | ||
| Restricted cash | $1.4M | $0 | $0 | |
| Property and equipment, net | $10.5M | $11.5M | ||
| Intangible assets, net | $569.5M | $521.9M | ||
| Goodwill | $124.9M | $117.0M | $117.0M | |
| Deferred income tax assets, net | $38.4M | $0 | ||
| Other assets | $63.8M | $31.5M | ||
| Total assets | $1.5B | $1.4B | ||
| Accounts payable and accrued liabilities | $107.8M | $76.4M | ||
| Accrued product returns and rebates | $161.1M | $168.7M | ||
| Contingent consideration, current portion | $31.1M | $47.3M | ||
| Other current liabilities | $38.2M | $0 | ||
| Total current liabilities | $338.2M | $292.4M | ||
| Contingent consideration, long-term | $206.0K | $0 | ||
| Operating lease liabilities, long-term | $30.4M | $27.4M | ||
| Deferred income tax liabilities, net | $0 | $5.0M | ||
| Other liabilities | $22.2M | $7.6M | ||
| Total liabilities | $390.9M | $332.3M | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 57,457,462 and 55,743,095 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $57.0K | $56.0K | ||
| Additional paid-in capital | $543.8M | $479.4M | ||
| Accumulated other comprehensive loss, net of tax | -$44.0K | -$189.0K | ||
| Retained earnings | $517.9M | $556.4M | ||
| Total stockholders' equity | $1.1B | $1.0B | $921.5M | $886.2M |
| Total liabilities and stockholders' equity | $1.5B | $1.4B | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 130.0M shares | 130.0M shares | ||
| Common stock, issued (in shares) | 57.5M shares | 55.7M shares | ||
| Common stock, outstanding (in shares) | 57.5M shares | 55.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $128.4M | $69.3M | $75.1M | |
| Marketable securities | $180.2M | $384.3M | ||
| Accounts receivable, net | $187.8M | $142.1M | ||
| Inventories, net | $82.4M | $54.3M | ||
| Prepaid expenses and other current assets | $65.3M | $36.1M | ||
| Total current assets | $644.2M | $686.1M | ||
| Restricted cash | $1.4M | $0 | $0 | |
| Property and equipment, net | $10.5M | $11.5M | ||
| Intangible assets, net | $569.5M | $521.9M | ||
| Goodwill | $124.9M | $117.0M | $117.0M | |
| Deferred income tax assets, net | $38.4M | $0 | ||
| Other assets | $63.8M | $31.5M | ||
| Total assets | $1.5B | $1.4B | ||
| Accounts payable and accrued liabilities | $107.8M | $76.4M | ||
| Accrued product returns and rebates | $161.1M | $168.7M | ||
| Contingent consideration, current portion | $31.1M | $47.3M | ||
| Other current liabilities | $38.2M | $0 | ||
| Total current liabilities | $338.2M | $292.4M | ||
| Contingent consideration, long-term | $206.0K | $0 | ||
| Operating lease liabilities, long-term | $30.4M | $27.4M | ||
| Deferred income tax liabilities, net | $0 | $5.0M | ||
| Other liabilities | $22.2M | $7.6M | ||
| Total liabilities | $390.9M | $332.3M | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 57,457,462 and 55,743,095 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $57.0K | $56.0K | ||
| Additional paid-in capital | $543.8M | $479.4M | ||
| Accumulated other comprehensive loss, net of tax | -$44.0K | -$189.0K | ||
| Retained earnings | $517.9M | $556.4M | ||
| Total stockholders' equity | $1.1B | $1.0B | $921.5M | $886.2M |
| Total liabilities and stockholders' equity | $1.5B | $1.4B | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 130.0M shares | 130.0M shares | ||
| Common stock, issued (in shares) | 57.5M shares | 55.7M shares | ||
| Common stock, outstanding (in shares) | 57.5M shares | 55.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net earnings (loss) | -$38.5M | $73.9M | $1.3M |
| Depreciation and amortization | $91.6M | $80.4M | $84.9M |
| Intangible asset impairment charges | $0 | $0 | $20.2M |
| Amortization of deferred financing costs and debt discount | $0 | $0 | $532.0K |
| Realized loss (gains) from sales of marketable securities | $439.0K | -$9.0K | $0 |
| Amortization of premium/discount on marketable securities | -$1.5M | $1.8M | -$122.0K |
| Change in fair value of contingent consideration | $25.4M | -$6.1M | -$1.5M |
| Share-based compensation expense | $33.1M | $27.8M | $26.8M |
| Deferred income tax benefit | $5.2M | -$20.1M | -$25.7M |
| Inventory valuation write-down | $1.9M | $8.9M | $8.0M |
| Payment of contingent consideration | -$4.9M | $0 | $0 |
| Noncash lease expense | $8.0M | $5.5M | $6.5M |
| Other noncash adjustments, net | $1.9M | $2.1M | -$606.0K |
| Accounts receivable | -$22.3M | $2.1M | $18.8M |
| Inventories | -$7.5M | $15.8M | $6.1M |
| Prepaid expenses and other assets | -$13.2M | -$19.4M | -$334.0K |
| Accrued product returns and rebates | -$7.6M | $14.4M | $2.6M |
| Accounts payable and other liabilities | -$24.6M | -$15.0M | -$36.3M |
| Net cash provided by operating activities | $47.3M | $172.0M | $111.1M |
| Acquisition of Sage, net of cash acquired | -$293.1M | $0 | $0 |
| Purchases of marketable securities | -$475.9M | -$688.0M | -$101.6M |
| Maturities of marketable securities | $774.5M | $498.9M | $370.9M |
| Purchases of property and equipment | -$1.3M | -$725.0K | -$551.0K |
| Net cash provided by (used in) investing activities | $4.1M | -$189.9M | $268.7M |
| Proceeds from Credit Line | $0 | $0 | $93.0M |
| Payments on Credit Line | $0 | $0 | -$93.0M |
| Payment on convertible notes | $0 | $0 | -$402.5M |
| Proceeds from issuance of common stock | $37.6M | $14.9M | $6.6M |
| Employee taxes paid related to net share settlement of equity awards | -$4.2M | -$2.7M | -$2.0M |
| Payment of contingent consideration | -$24.3M | $0 | $0 |
| Net cash provided by (used in) financing activities | $9.1M | $12.2M | -$397.9M |
| Net change in cash, cash equivalents, and restricted cash | $60.6M | -$5.7M | -$18.1M |
| Cash paid for income taxes | $16.1M | $53.3M | $36.6M |
| Cash paid for interest on debt | $0 | $0 | $1.9M |
No quarter-by-quarter statement was filed.
Corporate structure
SUPERNUS PHARMACEUTICALS, INC. sits at the top of its group. 9 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of SUPERNUS PHARMACEUTICALS, INC.
- MILLENNIUM MANAGEMENT LLC Filed SCHEDULE 13G/A on SUPERNUS PHARMACEUTICALS, INC., latest Aug 6, 2026 (3 filings since Feb 2, 2026)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on SUPERNUS PHARMACEUTICALS, INC., latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on SUPERNUS PHARMACEUTICALS, INC., latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on SUPERNUS PHARMACEUTICALS, INC., latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on SUPERNUS PHARMACEUTICALS, INC., latest Feb 17, 2026 (9 filings since Feb 15, 2022)
- DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G/A on SUPERNUS PHARMACEUTICALS, INC., latest Jan 21, 2026 (2 filings since Oct 31, 2024)
- BlackRock Filed SCHEDULE 13G/A on SUPERNUS PHARMACEUTICALS, INC., latest Apr 22, 2025 (5 filings since Jan 26, 2022)
- Macquarie Group Filed SC 13G/A on SUPERNUS PHARMACEUTICALS, INC., latest Nov 1, 2024 (2 filings since Feb 14, 2024)
- SUPERNUS PHARMACEUTICALS, INC. Rockville, Maryland, United States
- Adamas Holdings, LLC Subsidiary · Delaware, United States
- Adamas Operations, LLC Subsidiary · Delaware, United States
- Adamas Pharmaceuticals, LLC Subsidiary · Delaware, United States
- Biscayne Neurotherapeutics, Inc. Subsidiary · Delaware, United States
- MDD US Enterprises, LLC Subsidiary · Delaware, United States
- MDD US Operations, LLC Subsidiary · Delaware, United States
- Sage Securities Corporation Subsidiary · Massachusetts, United States
- Sage Therapeutics, LLC Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What SUPERNUS PHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $28.8M6 Dec 31, 2025 | $29.4M6 Dec 31, 2024 | −2.0% |
| Accumulated depreciation | $18.3M6 Dec 31, 2025 | $17.8M6 Dec 31, 2024 | +2.4% |
| Property and equipment, net | $10.5M6 Dec 31, 2025 | $11.5M6 Dec 31, 2024 | −8.8% |
| Operating-lease assets (leased space) | $26.7M6 Dec 31, 2025 | $24.5M6 Dec 31, 2024 | +9.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $128.4M6 Dec 31, 2025 | $69.3M6 Dec 31, 2024 | +85.3% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $124.9M6 Dec 31, 2025 | $117.0M6 Dec 31, 2024 | +6.7% |
| Intangible assets, net (excluding goodwill) | $569.5M6 Dec 31, 2025 | $521.9M6 Dec 31, 2024 | +9.1% |
| Accumulated amortization | $396.7M6 Dec 31, 2025 | $307.2M6 Dec 31, 2024 | +29.1% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $112.5M6 Dec 31, 2025 | $54.3M6 Dec 31, 2024 | +107.2% |
| Work in process | $29.4M6 Dec 31, 2025 | $26.7M6 Dec 31, 2024 | +10.1% |
| Finished goods | $21.1M6 Dec 31, 2025 | $16.4M6 Dec 31, 2024 | +28.4% |
Properties, in its own words
Our principal executive offices are located at 9715 and 9717 Key West Avenue, Rockville, Maryland, where we occupy approximately 136,016 square feet of laboratory and office space. The term of this lease commenced on February 1, 2019, and shall continue until April 30, 2034. We believe that these facilities are sufficient for our present and contemplated operations.
Item 2 of the 10-K filed Mar 2, 2026.5
Leadership
Who has led SUPERNUS PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
201520202025
- Chief executive officerJack A. Khattar Apr 30, 2012 to now13
- PresidentTimothy C. Dec Aug 24, 2021 to now14
- PresidentJack A. Khattar Apr 30, 2012 to Aug 24, 202113
- Chief financial officerTimothy C. Dec Aug 24, 2021 to now14
- Chief financial officerGregory S. Patrick Apr 30, 2012 to Nov 10, 202015
Board members and other officers (19)
- SVP, Commercial OperationsWilliam Todd Horich Mar 10, 2026 to now16
- Sr VP, Quality, GMP Oper. & ITFrank Mottola Feb 25, 2020 to now17
- Senior Vice President of SalesVictor Vaughn Jan 24, 2013 to Apr 20, 201818
- VP of Business DevelopmentJones W. Bryan Apr 30, 2012 to Mar 31, 201519
- Sr. VP of IP; CSOPadmanabh P. Bhatt Apr 30, 2012 to now20
- VP of Regulatory AffairsTami Tillotson Martin Apr 30, 2012 to Feb 27, 202421
- Executive Vice President R&DStefan K.f. Schwabe Sep 7, 2012 to Dec 22, 202022
- Board memberBethany Sensenig Aug 21, 2023 to now23
- Board memberCarrolee Barlow Jul 2, 2018 to now24
- Board memberGeorges Gemayel Mar 23, 2015 to now25
- Board memberCharles W. Newhall Iii. Apr 30, 2012 to now26
- Board memberFrederick M. Hudson Apr 30, 2012 to now27
- Board memberJack A. Khattar Apr 30, 2012 to now13
- Board memberJohn M. Siebert Apr 30, 2012 to Feb 27, 202428
- Board memberM. James Barrett Apr 30, 2012 to Mar 24, 201629
- Board memberMichael B. Sheffery Apr 30, 2012 to May 7, 201230
- Board memberMichael Bigham Apr 30, 2012 to Mar 26, 201331
- Board memberWilliam A. Nuerge Apr 30, 2012 to Jun 15, 201732
- Board memberSamuel D. Isaly May 8, 2012 to May 8, 201233
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Adamas Holdings, LLC Delaware4
- Adamas Operations, LLC Delaware4
- Adamas Pharmaceuticals, LLC Delaware4
- Biscayne Neurotherapeutics, Inc. Delaware4
- MDD US Enterprises, LLC Delaware4
- MDD US Operations, LLC Delaware4
- Sage Securities Corporation Massachusetts4
- Sage Therapeutics, LLC Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- SUPERNUS PHARMACEUTICALS INCMar 6, 2006 to Jun 12, 20193
Timeline
- Oct 15, 20268-K Shareholder vote34
- Aug 3, 20268-K Entered a material agreement; Executive or director change; Other events35
- Aug 3, 20268-K Results of operations36
- Aug 3, 20268-K Other events37
- Aug 3, 20268-K Other events38
- Jul 22, 20268-K Results of operations39
- Jun 18, 20268-K Shareholder vote40
- May 20, 20268-K New debt or obligation41
- May 5, 20268-K Results of operations42
- Apr 22, 20268-K Results of operations43
- Apr 7, 20268-K Entered a material agreement; Completed an acquisition or sale44
- Feb 24, 20268-K Results of operations45
- Apr 30, 2012New chief executive Jack A. Khattar becomes CEO13
- Mar 30, 2005Founded SUPERNUS PHARMACEUTICALS, INC. is founded2
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.46 a share, on Nov 4, 2025.46
When it reported results
- Aug 3, 2026Reported quarterly or annual results36
- Jul 22, 2026Reported quarterly or annual results39
- May 5, 2026Reported quarterly or annual results42
- Apr 22, 2026Reported quarterly or annual results43
- Feb 24, 2026Reported quarterly or annual results45
- Feb 12, 2026Reported quarterly or annual results47
- Nov 4, 2025Reported quarterly or annual results48
- Oct 21, 2025Reported quarterly or annual results49
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
528 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 95 major events, 279 insider forms, 27 large holders, 107 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Oct 6, 2026425 EDGAR
- Oct 6, 2026DEFA14A EDGAR
- Sep 11, 2026DEFM14A EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 6, 2026SCHEDULE 13G/A EDGAR
- Aug 4, 2026425 EDGAR
- Aug 3, 202610-Q EDGAR
- Aug 3, 20268-K EDGAR
- Aug 3, 2026425 EDGAR
- Aug 3, 2026DEFA14A EDGAR
- Aug 3, 2026425 EDGAR
- Aug 3, 20268-K EDGAR
- Aug 3, 2026DEFA14A EDGAR
- Aug 3, 2026425 EDGAR
- Aug 3, 20268-K EDGAR
The 528 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
87 open-market trades by officers, directors and large owners since October 2021: 0 buys and 87 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 7,250 | $49.60 | $359.6K | Form 4 |
| Mar 17, 2026 | Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 50,000 | $50.30 | $2.5M | Form 4 |
| Mar 16, 2026 | Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 50,000 | $50.28 | $2.5M | Form 4 |
| Mar 13, 2026 | Khattar Jack A.President, CEO | Sale | 35,000 | $50.38 | $1.8M | Form 4 |
| Mar 12, 2026 | Hudson Frederick M.Director | Sale | 5,369 | $50.61 | $271.7K | Form 4 |
| Mar 10, 2026 | Horich William ToddSVP, Commercial Operations | Sale | 4,439 | $55.00 | $244.1K | Form 4 |
| Mar 9, 2026 | Horich William ToddSVP, Commercial Operations | Sale | 4,438 | $54.00 | $239.7K | Form 4 |
| Mar 9, 2026 | Mottola FrankSVP, Chief Tech. Ops. Officer | Sale | 1,623 | $53.65 | $87.1K | Form 4 |
| Mar 6, 2026 | GEMAYEL GEORGESDirector | Sale | 8,787 | $53.00 | $465.7K | Form 4 |
| Mar 5, 2026 | GEMAYEL GEORGESDirector | Sale | 10,000 | $53.71 | $537.1K | Form 4 |
| Feb 19, 2026 | Sensenig BethanyDirector | Sale | 4,475 | $51.01 | $228.3K | Form 4 |
| Dec 19, 2025 | Mottola FrankSVP, Chief Tech. Ops. Officer | Sale | 20,000 | $50.41 | $1.0M | Form 4 |
| Dec 18, 2025 | Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 710 | $44.44 | $31.6K | Form 4 |
| Oct 9, 2025 | Khattar Jack A.President, CEO | Sale | 59,900 | $50.57 | $3.0M | Form 4 |
| Oct 9, 2025 | NEWHALL CHARLES W IIIDirector | Sale | 25,000 | $50.77 | $1.3M | Form 4 |
| Oct 2, 2025 | Khattar Jack A.President, CEO | Sale | 1,904 | $48.06 | $91.5K | Form 4 |
| Oct 1, 2025 | Khattar Jack A.President, CEO | Sale | 40,173 | $48.07 | $1.9M | Form 4 |
| Sep 30, 2025 | Khattar Jack A.President, CEO | Sale | 8,588 | $48.25 | $414.4K | Form 4 |
| Sep 29, 2025 | Khattar Jack A.President, CEO | Sale | 10,235 | $48.02 | $491.5K | Form 4 |
| Sep 23, 2025 | Khattar Jack A.President, CEO | Sale | 29,513 | $47.23 | $1.4M | Form 4 |
All 87 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 3 filings Feb 2, 2026 to Aug 6, 202650
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202651
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202652
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 202653
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 9 filings Feb 15, 2022 to Feb 17, 202654
- DIMENSIONAL FUND ADVISORS LPSCHEDULE 13G/A, 2 filings Oct 31, 2024 to Jan 21, 202655
- BlackRockSCHEDULE 13G/A, 5 filings Jan 26, 2022 to Apr 22, 202556
- Macquarie GroupSC 13G/A, 2 filings Feb 14, 2024 to Nov 1, 202457
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Jack A. KhattarChief Executive Officer, President & Secretary | 64 | $1.0M | $15.5M58 |
| 2025 | Timothy C. DecSenior Vice President, Chief Financial Officer | 67 | $504.9K | $1.9M58 |
| 2025 | Jonathan Rubin, MDSenior Vice President, Chief Medical Officer Research and Development | 64 | $485.1K | $1.4M58 |
| 2025 | Padmanabh P. Bhatt, Ph.D.Senior Vice President, Intellectual Property, Chief Scientific Officer | 68 | $455.9K | $1.4M58 |
| 2025 | Frank MottolaSenior Vice President, Chief Technical Operations Officer | 54 | $412.5K | $1.4M58 |
| 2024 | Jack A. KhattarChief Executive Officer, President & Secretary | 64 | $5.2M | $826.3K58 |
| 2024 | Timothy C. DecSenior Vice President, Chief Financial Officer | 67 | $485.5K | $229.2K58 |
| 2024 | Jonathan Rubin, MDSenior Vice President, Chief Medical Officer Research and Development | 64 | $466.4K | $192.5K58 |
| 2024 | Padmanabh P. Bhatt, Ph.D.Senior Vice President, Intellectual Property, Chief Scientific Officer | 68 | $440.5K | $163.4K58 |
| 2024 | Frank MottolaSenior Vice President, Chief Technical Operations Officer | 54 | $377.4K | $140.0K58 |
| 2023 | Jack A. KhattarChief Executive Officer, President & Secretary | 64 | $963.0K | $13.3M58 |
| 2023 | Frank MottolaSenior Vice President, Chief Technical Operations Officer | 54 | $352.7K | $1.8M58 |
| 2023 | Jonathan Rubin, MDSenior Vice President, Chief Medical Officer Research and Development | 64 | $440.0K | $1.6M58 |
| 2023 | Padmanabh P. Bhatt, Ph.D.Senior Vice President, Intellectual Property, Chief Scientific Officer | 68 | $427.7K | $1.5M58 |
| 2023 | Timothy C. DecSenior Vice President, Chief Financial Officer | 67 | $453.8K | $39.6K58 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 9,350,046 | $434.9M | 0.0% | +552,792 |
| Millennium Management LLC | 3,853,212 | $179.2M | 0.1% | +537,239 |
| Vanguard Portfolio Management LLC | 3,305,429 | $153.7M | 0.0% | +66,736 |
| Armistice Capital, LLC | 2,646,201 | $123.1M | 3.4% | +750,854 |
| Vanguard Capital Management LLC | 2,516,721 | $117.1M | 0.0% | +49,506 |
| State Street Corp | 2,459,828 | $114.4M | 0.0% | +171,701 |
| Nomura Asset Management International Inc. | 2,378,329 | $110.6M | 0.2% | +341,127 |
| Dimensional Fund Advisors LP | 2,078,090 | $96.7M | 0.0% | −228,940 |
| Geode Capital Management, LLC | 1,570,088 | $73.0M | 0.0% | −53,426 |
| Stephens Investment Management Group LLC | 1,485,821 | $69.1M | 0.7% | +134,490 |
| Renaissance Technologies LLC | 1,478,180 | $68.8M | 0.1% | −227,042 |
| Loomis Sayles & Co L P | 1,475,192 | $68.6M | 0.1% | +49,413 |
| Citadel Advisors LLC | 1,373,982 | $63.9M | 0.0% | −119,464 |
| Two Sigma Investments, LP | 1,184,378 | $55.1M | 0.0% | +913,150 |
| Sofinnova Investments, Inc. | 1,036,328 | $48.2M | 2.6% | +82,019 |
| Qube Research & Technologies Ltd | 922,166 | $42.9M | 0.0% | +423,968 |
| Morgan Stanley | 876,841 | $40.8M | 0.0% | −37,052 |
| Goldman Sachs Group Inc | 819,432 | $38.1M | 0.0% | −37,055 |
| D. E. Shaw & Co., Inc. | 767,668 | $35.7M | 0.0% | +145,218 |
| Northern Trust Corp | 733,374 | $34.1M | 0.0% | +33,918 |
| Woodline Partners LP | 708,276 | $32.9M | 0.1% | +259,280 |
| Charles Schwab Investment Management Inc | 703,552 | $32.7M | 0.0% | −2,424 |
| Bank Of America Corp /de/ | 621,102 | $28.9M | 0.0% | −93,124 |
| Ashford Capital Management Inc | 613,783 | $28.5M | 3.1% | −31,598 |
| Soleus Capital Management, L.P. | 520,000 | $24.2M | 0.8% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −40.3% | Report |
| Dec 11, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −26.2% | Report |
| Oct 9, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +34.4% | Report |
| Mar 24, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −12.4% | Report |
| Dec 23, 2022 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +95.0% | Report |
| Nov 13, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −42.1% | Report |
| Jul 17, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −75.0% | Report |
| Jun 1, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −85.3% | Report |
| May 28, 2020 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | −91.8% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How SUPERNUS PHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSUPERNUS PHARMACEUTICALS, INC.1
- CIK0001356576
- Employer ID (EIN)20-25901845
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address9715 Key West Avenue, Rockville, MD 208501
- Phone301-838-25001
- Shares outstanding58,127,013 as of Jul 28, 202611
- Public float$1.7B as of Jun 30, 20255
- AuditorKPMG LLP, Baltimore, Maryland PCAOB ID 185; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceMar 6, 20061
- Filings1,185 in all: 4 (495), 8-K (307), 144 (67), 10-Q (44), SC 13G/A (33), 3 (26), 4/A (15), SC 13D/A (15)1
All 45 form types
UPLOAD (15), 10-K (14), DEF 14A (14), DEFA14A (13), SC 13G (13), CORRESP (11), SCHEDULE 13G/A (10), S-1/A (9), ARS (7), CT ORDER (7), S-8 (7), 425 (6), 8-K/A (6), SC 13D (6), NT 10-K (4), NT 10-Q (4), SC TO-T/A (4), 10-Q/A (3), EFFECT (3), SC TO-C (3), SCHEDULE 13G (3), 424B4 (2), 5 (2), FWP (2), S-1 (2), SC TO-T (2), 10-K/A (1), 3/A (1), 8-A12B (1), CERTNAS (1), D (1), D/A (1), DEFM14A (1), PRE 14A (1), REGDEX/A (1), S-3 (1), S-8 POS (1)
- Latest filingsAnnual report (10-K) Mar 2, 2026
Quarterly report (10-Q) Aug 3, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Oct 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 Par Value | SUPN | NASDAQ Stock Market LLC |
From the cover page of the 10-K filed Mar 2, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks SUPERNUS PHARMACEUTICALS, INC. names in Item 1A of its 10-K filed Mar 2, 2026: 57 risks under these headings, as written.5
- Risks Related to Our Industry and Business
- We are dependent on the commercial success of our products in the U.S.
- If other versions of our products, including but not limited to generics containing one or more of the active pharmaceutical ingredients present in our products are approved and successfully commercialized, or if products are developed, approved and successfully commercialized which provide similar benefits of treatment for patients, our business could be materially harmed.
- We are subject to uncertainty relating to payment or managed care reimbursement policies, which, if not favorable for our products or product candidates, could hinder or prevent our commercial success.
- We depend on wholesalers, distributors, and specialty pharmacies for the distribution of our products. If we lose any of our significant wholesaler, distributor, or specialty pharmacy accounts, our business could be harmed.
- We may not be able to effectively market and sell our product candidates, if approved, in the U.S.
- Final marketing approval of any of our product candidates or approval of additional indications for existing products by the FDA or other regulatory authorities may be delayed, limited, or denied, any of which would adversely affect our ability to generate operating revenues.
- If we do not obtain marketing exclusivity for our product candidates, our business may suffer.
- If the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, the sales of our products or the commercial success of our product candidates would be adversely affected.
- If our competitors develop or market alternatives for the treatment of our target indications, our commercial opportunities will be reduced or eliminated.
- Our products and our product candidates may be subject to restrictions or withdrawal from the market. We may be subject to penalties if we fail to comply with regulatory requirements.
- We depend on collaborators to work with us to develop, manufacture and commercialize their and our products and product candidates. We have in-licensed or acquired a portion of our intellectual property necessary to develop certain of our product candidates. If we fail to comply with our obligations under any of these arrangements, we could lose the benefit of such collaborative relationships, including licenses or intellectual property rights.
The other 46 risks
- Even if our product candidates receive regulatory approval in the U.S., we or our collaborators may not receive approval to commercialize our product candidates outside of the U.S.
- Our failure to successfully develop and market our product candidates would impair our ability to grow.
- Recent Executive Orders May Impact our Financial Results.
- We may be unable to acquire product candidates or products.
- Our clinical trials for our product candidates may fail to demonstrate acceptable levels of safety, efficacy, or other requirements, which could prevent or significantly delay regulatory approval.
- Delays or failures in the completion of clinical development of our product candidates would increase our costs, and delay, or limit our ability to generate revenues.
- Our products and product candidates may cause undesirable side effects or have other characteristics that limit their commercial potential, delay, or prevent their regulatory approval.
- We may not obtain or maintain the benefits associated with designation as an orphan drug under the Orphan Drug Act, including market exclusivity.
- Healthcare reform measures could hinder or prevent the commercial success of our products or product candidates.
- Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects.
- Any failure to comply with healthcare regulations, including implementation of any change in compliance with healthcare regulations and laws could cause us to incur significant compliance expenses and any failure to comply could subject us to substantial penalties and fines. Our business, operations, and financial condition could be adversely affected.
- Guidelines and recommendations published by various organizations can reduce the use of our products and product candidates.
- We could be involved in additional lawsuits to protect or enforce our patents, which could be expensive, time consuming, distracting, and ultimately unsuccessful.
- Limitations on our patent rights relating to our products and product candidates may limit our ability to prevent third parties from competing with us.
- If we are sued for infringing the intellectual property rights of third parties, it could be costly and time consuming to defend such a suit. An unfavorable outcome in such litigation could have a material adverse effect on our business.
- We face potential litigation and product liability exposures. If successful claims are brought against us, we may incur substantial liabilities.
- As we continue to increase the size of our organization, we may experience difficulties in managing growth.
- Cybersecurity incidents may adversely impact our financial condition, results of operations, and reputation. Security breaches and other disruptions could compromise our information and expose us to liability which would cause our business and reputation to suffer.
- We face significant competition in attracting and retaining talented employees. Further, managing succession for and retention of key executives is critical to our success. Our failure to do so could have an adverse impact on our future performance.
- Our business involves the use of hazardous materials, and we must comply with environmental laws and regulations. This can be expensive and restrict how we do business.
- Provisions in our agreement with Shire, or its successor, Takeda Pharmaceutical Company Limited, impose restrictive covenants on us, which could limit our ability to operate effectively in the future.
- The Company’s financial condition and results of operations may be materially and adversely affected by health pandemics.
- Ongoing legal actions and proceedings could distract management and could result in substantial costs or large judgments against Supernus or one or more of its subsidiaries.
- Risks Related to Our Finances and Capital Requirements
- Tariffs may increase our costs.
- Our operating results may fluctuate significantly.
- Our ability to use our net operating loss carryforwards and other tax attributes may be limited or may expire prior to utilization.
- In the past, we have identified material weaknesses in our internal controls which might cause stockholders to lose confidence in our financial and other public reporting, particularly if not remediated appropriately and timely, which in turn would harm our business and the trading price of our common stock.
- We have and may further expand our business through acquisitions of new product lines or businesses, which expose us to various risks, including difficulties in integrating acquisitions. Our recent acquisitions pose certain incremental risks to the Company.
- Any impairment in the value of our intangible assets, including goodwill, could negatively affect our operating results and total capitalization.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
- Although we have historically been profitable from operations since the fourth quarter of 2014, there is no assurance that we will continue to generate net income in the future. We may not be able to maintain or increase profitability.
- Risks Related to Securities Markets and Investment in Our Stock
- The issuance of additional shares of our common stock, or instruments convertible into or rights to acquire shares or our common stock, or market sales of our common stock, could affect the market price of our common stock.
- The price of our common stock may fluctuate substantially.
- Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could negatively impact the market price of our common stock.
- To the extent outstanding stock options are exercised and restricted stock units and performance stock units vest there will be dilution to new investors.
- Indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition, and results of operations, and impair our ability to satisfy our obligations under the notes.
- Our Credit Line is an uncommitted debt facility that may be terminated by the lender at any time.
- General Risk Factors
- Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Our insurance coverage may not be sufficient to cover our legal claims or other losses that we may incur in the future.
- We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
- We may enter into significant, complex, and unusual transactions, which may require us to engage outside consultants and financial professionals in order to comply with complex accounting and reporting requirements.
- Our operations rely on sophisticated information technology, systems, and infrastructure, a disruption of which could harm our operations.
- We may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs, commercialization, or business development efforts.
- Complying with increased financial reporting and securities laws reporting requirements has increased our costs and requires additional management resources. We may fail to meet these obligations.
- We have never paid dividends. Because we do not anticipate paying any cash dividends in the foreseeable future, capital appreciation, if any, of our common stock will be your sole source of gain on an investment in our common stock.
- Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
Legal proceedings
From time to time and in the ordinary course of business, Supernus Pharmaceuticals, Inc. (Company) and any of its subsidiaries may be subject to various claims, charges and litigation. Parent and any of its subsidiaries may be required to file infringement claims against third parties for the infringement of our patents.
I. Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, et al., C.A. No. 21-cv-6964 (GC)(DEA) (D.N.J.)
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARTimothy C. Dec, President
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARBethany Sensenig, Board member
- 24SEC EDGARCarrolee Barlow, Board member
- 25SEC EDGARGeorges Gemayel, Board member
- 26
- 27SEC EDGARFrederick M. Hudson, Board member
- 28SEC EDGARJohn M. Siebert, Board member
- 29SEC EDGARM. James Barrett, Board member
- 30SEC EDGARMichael B. Sheffery, Board member
- 31SEC EDGARMichael Bigham, Board member
- 32SEC EDGARWilliam A. Nuerge, Board member
- 33SEC EDGARSamuel D. Isaly, Board member
- 34SEC EDGARShareholder vote
- 35
- 36SEC EDGARResults of operations
- 37SEC EDGAROther events
- 38SEC EDGAROther events
- 39SEC EDGARResults of operations
- 40SEC EDGARShareholder vote
- 41SEC EDGARNew debt or obligation
- 42SEC EDGARResults of operations
- 43SEC EDGARResults of operations
- 44
- 45SEC EDGARResults of operations
- 46NasdaqNasdaq calendar
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58